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Abstract 
Hymenochirin-1b (Hym-1B; IKLSPETKDNLKKVLKGAIKGAIAVAKMV.NH2) is a cationic, 
α-helical amphibian host-defense peptide with antimicrobial, anticancer, and immunomodulatory 
properties. This study investigates the abilities of the peptide and nine analogs containing 
substitutions of Pro5, Glu6, and Asp9 by either L-lysine or D-lysine to stimulate insulin release in 
vitro using BRIN-BD11 clonal β-cells or isolated mouse islets and in vivo using mice fed a high 
fat diet to produce obesity and insulin resistance. Hym-1B produced a significant and 
concentration-dependent increase in the rate of insulin release from BRIN-BD11 cells without 
cytotoxicity at concentrations up to 1 µM with a threshold concentration of 1nM. The threshold 
concentrations for the analogues were: [P5K], [E6K], [D9K], [P5K,E6K] and [E6K,D9k]  
0.003nM, [E6K,D9K] and [D9k] 0.01nM , [P5K,D9K] 0.1 nM  and [E6k] 0.3 nM. All peptides 
displayed cytotoxicity at concentrations ≥ 1 µM except the [P5K] and [D9k] analogues which were 
non-toxic at 3 µM. The potency and maximum rate of insulin release from mouse islets produced 
by the [P5K] peptide were significantly greater than produced by Hym-1B. Neither Hym-1B nor 
the [P5K] analogue at 1 µM concentration had an effect on membrane depolarization or 
intracellular Ca2+. The [P5K] analogue (1 µM) produced a significant increase in cAMP 
concentration in BRIN-BD11 cells and stimulated GLP-1 secretion from GLUTag cells. Down-
regulation of the protein kinase A pathway by overnight incubation with forskolin completely 
abolished the insulin-releasing effects of [P5K]hym-1B. Intraperitoneal administration of the 
[P5K] and [D9k] analogues (75nmol/kg body weight) to high fat-fed mice with insulin resistance 
significantly enhanced glucose tolerance with a concomitant increase in insulin secretion. We 
conclude that [P5K]hym-1B and [D9k]hym-1B show potential for  development into anti-diabetic 
agents. 
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Abbreviations:  
LDH = Lactate dehydrogenase                                                                                                                                  
Hym-1B = Hymenochirin-1b 
[Ca2+]i = Intracellular calcium concentration 
IBMX = 3-isobutyl-1-methylxanthine 
PKC = Protein kinase C 
PKA =  Protein Kinase A 
GLP-1 = Glucagon-like peptide 1 
TNF-α = Tumor necrosis factor α 
IL-17 = Interleukin 17 
CPF-6 = Caerulein precursor fragment 6 
PMA = Para-Methoxyamphetamine 
MALDI-TOF = Matrix-assisted laser desorption/ionization time of flight 
EGTA = ethylene glycol tetraacetic acid 
CCK8 = Cholecytokinin 8 
HEPES = 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
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Introduction 
The global epidemic of Type 2 diabetes has intensified the search for new therapeutic 
options to achieve and sustain glycaemic control and prevent diabetic complications (Peters 2010). 
Natural occurring bioactive compounds offer boundless opportunities for new anti-diabetic drug 
discovery and there is an increasing focus on the exploration of these sources (Mandal et al. 2014). 
Exendin-4 isolated from the venom of the Gila monster lizard was the first of such products to 
reach the market for the treatment of Type 2 diabetes (Tokuda et al. 2014). Host-defense peptides 
from the skins of several frog species have also demonstrated potential for development into novel 
anti-diabetic agents. Several such peptides that were first identified on the basis of their 
antimicrobial activities have subsequently been found to possess insulinotropic effects. These 
peptides are generally multifunctional displaying antimicrobial, anticancer, and antiviral activities 
[reviewed in (Conlon et al. 2014)].  
Clawed frogs of the family Pipidae are distributed into five genera (Hymenochirus, 
Pseudhymenochirus, Silurana, Xenopus and Pipa). All are indigenous to Africa except members 
of the genus Pipa which are found in South America. The genus Hymenochirus contains four 
species: H. boettgeri, H. boulengeri, H. curtipes and H. feae (Frost 2015).  Peptidomic analysis of 
the skin secretions of the Congo dwarf clawed frog H. boettgeri revealed the presence of five 
structural related peptides termed hymenochirins that have low structural similarity with the 
antimicrobial peptides isolated from skin secretions of other frogs (Mechkarska et al. 2012).  
Hymenochirin-1B (IKLSPETKDNLKKVLKGAIKGAIAVAKMV.NH2) displays 
multifunctional properties including antimicrobial (Mechkarska et al. 2012; 2013), 
immunomodulatory (Mechkarska et al. 2013), and anticancer activities (Attoub et al. 2013) but its 
insulinotropic effects have not yet been reported.  
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The disadvantages of naturally occurring peptides as therapeutic agents include short-half 
life in the circulation, toxicity, low potency and bioavailability, and significant immunogenicity 
(Lewis and Garcia 2003).  However, these limitations may be circumvented to varying degrees by 
the design of appropriate analogues (Avan et al. 2014). The hymenochirins adopt an amphipathic 
α-helical conformation in a membrane-mimetic solvent (50% trifluoroethanol-water) (Serra et al. 
2014). Studies with analogues of other α-helical, frog skin host-defense peptides have shown that 
increasing cationicity, while maintaining amphipathicity enhances both antimicrobial (Conlon et 
al. 2007) and anticancer (Attoub et al. 2013) and produces more potent and effective insulin-
releasing peptides (Abdel-Wahab et al. 2008b; 2010; Srinivasan et al. 2014). The aim of the present 
study was to investigate the insulinotropic actions of hymenochirin-1B, both in vitro using BRIN-
BD11 clonal β-cells or isolated mouse islets and in vivo using mice fed a high fat diet to produce 
obesity and insulin resistance. The effects of increasing cationicity by substitutions of neutral 
(Pro5) and acidic (Glu6 and Asp9) amino acids on the hydrophilic face of the α-helix by L-lysine 
or D-lysine on insulin-releasing and cytotoxic activities of the peptide were also determined. 
 
Results 
Effects of hymenochirin-1B and its analogues on insulin-release from BRIN-BD 11 cells 
The basal rate of insulin release from BRIN-BD11 cells in the presence of 5.6 mM glucose 
alone was 1.05 ± 0.06 ng/106 cells/20 min.  In the presence of the well-established insulin 
secretagogue, 10 mM alanine, the rate of insulin release increased to 6.49 ± 0.24 ng/106 cells/20 
min. Incubation with hymenochirin-1B produced a significant (P<0.05 to P<0.001) stimulatory 
response at concentrations ≥ 1nM (Fig. 1) with a 304%  increase above the basal rate  at 1µM 
(Table 1). At a concentration of 3 µM, the peptide significantly stimulated the release of LDH 
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from the cells indicating that the integrity of the plasma membrane had been compromised. All 
analogues tested showed greater insulin-releasing potency than the native peptide. The threshold 
concentration (minimum concentration producing a significant increase in secretion rate) for the 
[P5K], [E6K], [D9K], [P5K, E6K] and [E6K, D9K] analogues was 0.003nM, for the [E6K,D9K] 
and [D9k] analogues 0.01nM,  for [P5K,D9K]hym-1B 0.1M, and for [E6k]hym-1B 0.3 nM (Table 
1).  
The di-substituted [P5K,E6K], [P5K,D9K], and [E6K,D9K] analogues showed greater 
cytotoxicity compared to hym-1B producing a significant increase in the rate of LDH release at 
concentrations below 1 µM (Table 1). However, the [P5K] and [D9k] analogues were non-toxic 
at a concentration of 3 µM. Both peptides produced a significantly greater increase in the rate of 
insulin release at 3 µM compared with hym-1B at its maximum non-toxic concentration of 1 µM 
(Table 1). 
 
Effects of hym-1B and analogues on insulin release from isolated islets  
 
In the presence of 16.7 mM glucose, Hym-1B and its [P5K] and [D9k] analogues produced 
a concentration-dependent increase in the rate of insulin secretion from isolated mouse islets (Fig. 
2A). Significant stimulatory effects of hym-1B and [D9k]hym-1B were seen at concentrations ≥ 
10nM while [P5K]hym-1B showed a significant  stimulatory effect at 0.1nM (Table 2). The 
stimulatory effects of the  [P5K] and [D9k] analogues, measured as the % of total insulin content 
released, were significantly (P<0.001) greater than GLP-1 when tested at 1µM concentration 
(Table 2). These effects were not accompanied by significant release of LDH from isolated islets 
(Fig. 2B, Table 2).  
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Insulin-releasing activities of hym-1B and [P5K]hym-1B in the presence of known modulators of 
insulin release 
 
The mechanism of action of hym-1B and [P5K]hym-1B was investigated by performing 
incubations in presence of known modulators of insulin release. As shown in Table 3, the 
stimulatory actions of the peptides were maintained at 16.7 mM ambient glucose concentration 
and in the presence of K+ channel activator, diazoxide (300µM) and the blocker of L-type voltage-
dependent Ca2+ channels, verapamil (50 μM).  A KCl (30 mM) depolarising stimulus increased 
the rate of insulin release and this increase was significantly (P < 0.001) augmented by hym-1B 
(1.4-fold) and [P5K]hym-1B (1.9-fold). The stimulatory activities of the peptides were not 
significantly affected when incubations were performed in the absence of extracellular calcium 
(Table 4).  
 
Effects of peptides on membrane depolarization and intracellular calcium ([Ca2+]i) 
 
In the presence of 30mM KCl, a significant (96 %‚ P<0.001) increase in membrane 
depolarisation was observed in BRIN-BD11 cells. In contrast to the effects of KCl, hym-1B and 
[P5K]hym-1B had no effect on membrane depolarisation (Fig. 3). Similarly, alanine caused a 
significant (87%, P<0.001) increase in intracellular calcium concentration but no significant effect 
was observed with the peptides (Fig. 4). 
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Effects of [P5K]hym-1B on intracellular concentrations of cyclic AMP   
 
In order to determine which cell signalling pathway may be involved in the insulin-
releasing effects of [P5K]hym-1B, its effects on cAMP production in BRIN-BD11 cells were 
investigated. As shown in Fig. 5A, [P5K]hym-1B produced a significant (P<0.01) increase in 
cAMP concentration compared to 5.6mM glucose + 200µM IBMX. The stimulatory effects 
produced by [P5K]hym-1B (1 µM) was comparable to the effects produced by GLP-1 (10nM). 
Concomitantly, [P5K]hym-1B produced a significant (P<0.01) increase in the rate of insulin 
release compared to 5.6mM glucose alone and 5.6mM glucose + IBMX (200µM) under the same 
experimental condition (Fig. 5B).   
 
Effects of down-regulation of the PKC and PKA pathways on [P5K]hym-1B stimulated insulin 
release 
 
The experimental protocol made use of the fact that overnight culture of BRIN-BD11 cells 
with activators of the PKA pathway (forskolin) or the PKC pathway (PMA) blocks the subsequent 
stimulatory effects of agents that activate these pathways (McClenaghan et al., 2006). Following 
overnight culture in media alone, [P5K]hym-1B  and all control compounds exhibited insulin 
stimulatory effects which were significantly (P<0.001) higher than 5.6mM glucose alone (Fig. 6). 
Down-regulation of the PKA pathway with 25µM forskolin completely inhibited the insulin 
stimulatory activities of [P5K]hym-1B, GLP-1 and forskolin but not CCK8. In a second set of 
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experiment that involved down-regulation of the PKC pathway with PMA (10nM), [P5K]hym-1B, 
forskolin and GLP-1 retained their full stimulatory abilities but the effect of CCK8 was abolished.  
Down-regulation of both the PKA and PKC pathways by forskolin + PMA resulted in the loss of 
stimulatory response by all agents tested (Fig. 6). 
 
Effects of [P5K]hym-1B on GLP- 1 and LDH release from GLUTag cells 
 
As shown in Fig.7, [P5K]hym-1B produced a significant (P<0.001) increase in the rate of 
GLP-1 release from GLUTag cells. At 1µM, the peptide elicited a 66% increase in GLP-1 secretion 
cells over the basal rate in 2mM glucose while the positive control (10 mM glutamine) produced 
a 76% increase. The observed stimulatory effect on GLP-1 release was without cell toxicity at any 
concentration tested as evidenced by a lack of increase in the rate of LDH release (data not shown). 
 
Acute effects of [P5K]hym-1B and [D9k]hym-1B on glucose tolerance in high-fat fed mice 
 
No adverse effects were observed in the animals following administration of the peptides.  
Plasma glucose concentrations in obese, insulin-resistant mice receiving  intraperitoneal 
administration of [P5K]hym-1B (75nmol/kg body weight) were significantly less at 60 min after 
intraperitoneal injection of glucose compared to animals receiving vehicle only (Fig. 8A). The 
integrated response of plasma glucose (area under the curve) was significantly less after 
administration of vehicle only (Fig. 8B). Plasma insulin concentrations were significantly higher 
at 15 min after intraperitoneal injection of glucose in animals receiving [P5K]hym-1B (Fig. 8C)  
and the integrated response (total amount of insulin released over 60 min) was significantly greater 
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(2.2-fold; P < 0.001) (Fig. 8D). Similarly, plasma glucose concentration in animals receiving 
[D9k]hym-1B were significantly less at 60 min (Fig. 8E) and the integrated response of plasma 
glucose was also significantly less after administration of vehicle only (Fig. 8F). Plasma insulin 
concentrations after administration of [D9k]hym-1B were not significantly different at any time 
point  compared with vehicle only  (Fig. 8G) but the integrated response was significantly greater 
(1.7-fold; P < 0.01) (Fig. 8H). 
 
 
Discussion 
The present investigation has provided further demonstration that the frog skin host-
defense peptide hym-1B shows potential for development into a therapeutically valuable agent. 
Previous studies have shown that the peptide, and its [E6k,D9k] analogue, display high potency 
against clinical isolates of multidrug-resistant Gram-positive and Gram-negative bacteria 
(Mechkarska et al. 2013). A role for the peptides as anti-inflammmatory agents in treatment  sepsis 
is suggested by their ability to  stimulate the production of the anti-inflammatory cytokines IL-4 
and IL-10 by human peripheral blood mononuclear cells without significant effect on production 
of the pro-inflammatory cytokines TNF-α and IL-17 (Mechkarska et al. 2013). Furthermore, hym-
1B and the [D9k] analogue possess high cytotoxic potency against a range of human tumour cells 
but very low hemolytic activity against human erythrocytes (Attoub et al. 2013). These 
observations have now been extended to show that hym-1B and its lysine-containing analogues 
stimulate the rate of insulin release in vitro from both BRIN-BD11 rat clonal β-cells or isolated 
mouse islets and in vivo from mice fed a high-fat diet to induce insulin resistance.  Consequently, 
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these peptides show potential for development into agents for the treatment of patients with Type 
2 diabetes. 
The clinical usefulness of hym-1B as an anti-diabetic agent is limited by the fact that 
significant cytotoxicity against BRIN-BD11 was measured at concentrations greater than 1 µM 
although this concentration is 1000-times greater than the minimum concentration producing a 
significant increase in the rate of insulin release. The three-dimensional structure of hym-1B has 
not been determined but a nuclear magnetic resonance investigation of a structurally similar 
peptide from the same family, hymenochirin-1P has demonstrated that the peptide has a random 
coil conformation in water but, in the membrane-mimetic solvent 50% (v/v) trifluoroethanol-water 
adopts a well-defined conformation characterized by two α-helical domains from residues 6 to 17 
and from 21 to 28 with the N-terminal region unfolded (Serra et al., 2014). In order to develop 
analogues of hym-1B with increased insulinotropic potency and efficacy, the Pro5, Glu6 and Asp9 
amino acid residues in the first α-helical domain were substituted by one or more L-lysine or D-
lysine residues. All analogues tested showed great potency than the native peptide indicating that 
an increase in cationicity promotes insulin-releasing activity. This conclusion is consistent with 
the increased insulinotropic potency observed with [L18K]pseudin-2 (Abdel-Wahab et al 2008b), 
[D4K]B2RP (Abdel-Wahab et al 2010) and [G11K]alyteserin-2a (Ojo et al 2013a). The 
[P5K,E6K], [P5K,D9K], and [E6K,D9K] analogs were more cytotoxic to BRIN-BD11 cells and 
the [E6K], [D9K], [D6k], and [E6k,D9k] peptides were equally cytotoxic (Table 1). However, the 
present study has identified two analogues, [P5K]hym-1B and [D9k]hym-1B that display greater 
potency and efficacy  (response at the maximum non-toxic concentration) than hym-1B and are 
not cytotoxic at concentrations up to and including 3 µM. 
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Insulin secretion is regulated by two major signaling pathways: the KATP channel-
dependent and KATP channel-independent augmentation pathway (Henquin 2000). In the former 
pathway, insulin secretion is triggered by an increased [ATP]/[ADP] ratio, closure of ATP-
sensitive potassium channels and opening of voltage-dependent calcium channels. The influx of 
extracellular calcium and elevation of cytoplasmic intracellular calcium induce exocytosis of 
insulin. Previous studies with the frog skin peptides alyteserin-2a (Ojo et al. 2013a), tigerinin-1R 
(Ojo et al. 2013b), and CPF-6 (Srinivasan et al. 2013) using BRIN-BD11 cells and with a brevinin-
1 family peptide using RINm5F rat insulinoma-derived cells (Kim et al. 2010) have shown that 
the peptides produce cellular depolarization and increase intracellular calcium concentration 
consistent with their insulin-releasing activity being mediated by the KATP channel-dependent 
pathway.  In contrast, the insulin-releasing activities of brevinin-2GUb (Conlon et al. 2008), 
phylloseptin-L2 (Abdel-Wahab et al. 2008a), pseudin-2 (Abdel-Wahab et al. 2008b), and several 
temporin peptides (Abdel-Wahab et al. 2007) do not appear to involve an increase in intracellular 
Ca2+ concentrations. The maintenance of the insulin-releasing activity of [P5K]hym-1B in Ca2+-
free media and in the presence of potassium channel activator, diazoxide and the blocker of L-type 
voltage-dependent calcium channels, verapamil  suggests that the effects of the peptide are not 
mediated primarily by the KATP channel-dependent pathway. The augmentation by [P5K]hym-1B 
of the rate of insulin release produced by a depolarizing stimulus (30 mM KCl) may indicate that 
the peptide may be acting by an, as yet uncharacterized, KATP channel-independent pathway.   
Earlier studies by Green et al. (2004a; 2004b; 2004c) demonstrated that incubation of  
BRIN-BD11 cells with GLP-1 stimulated cAMP production and it has been speculated that 
signaling via the PKA pathway may contribute to the modulation of KATP independent pathway of 
insulin secretion by GLP-1 (McClenaghan et al. 2006).  [P5K]hym-1B also increases intracellular 
13 
 
cAMP concentration with concomitant  insulin release from BRIN-BD11 cells (Fig. 5)  and, in  
line with this observation, down-regulation of PKA pathway by forskolin abolishes the  
insulinotropic activity of the peptide (Fig. 6)  In contrast, down-regulation of the PKC pathway by 
PMA had no significant effect on insulin release. It is concluded, therefore, that insulinotropic 
activities of [P5K]hym-1B may involve the activation of PKA pathway 
The use of long-acting analogues of GLP-1 in the treatment of Type 2 diabetes is well 
established (Green et al. 2005). In addition to its potent insulinotropic properties, GLP-1 improves 
of glucose uptake in peripheral tissues, augments of insulin gene transcription and reverses the 
islet cell deterioration seen in type 2 diabetes (Green et al. 2004c; 2005; Meier et al. 2003; 
Pospisilik et al. 2003). Moreover, insulin release in response to GLP-1 is glucose dependent, a 
characteristic which places it at an advantage over other agents that may produce rebound 
hypoglycemia (Green et al. 2004c; 2005; Nattrass et al. 1999).  Previous studies have demonstrated 
the ability of several amphibian host-defense peptides such as maginin-AM2, PGLa and tigerinin-
1R to stimulate GLP-1 release from GLUTag cells (Ojo et al. 2013b). GLUTag cells are a useful 
model with which to identify candidates that stimulate GLP-1 release (Gribble et al. 2003). The 
ability of glutamine to stimulate GLP-1 secretion from GLUTag cells is well documented 
(Reimann et al. 2004; Tolhurst et al. 2011) so that it has been used it as positive control in this 
study. At 1µM concentration [P5K]hym-1B produces a significant  increase in the rate of GLP-1 
release from GLUTag cells that is comparable to that produced by 10 mM glutamine. 
Consequently, in addition to its direct insulinotropic action on the β-cells of the pancreas, 
[P5K]hym-1B may also promote the secretion of the incretin hormone GLP-1 from the L-cells of 
the intestine. 
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The high-fat fed mouse  is a useful model for understanding the effect of an energy dense 
high fat western diet on the onset of obesity and insulin resistance (Wang and Liao 2012) and the 
development of metabolic syndrome and Type 2 diabetes (Islam 2009; Zhang et al 2009).  Previous 
studies have shown that several host-defense peptides including brevinin-2-related peptide (Abdel-
Wahab et al. 2010), alyteserin-2a (Ojo et al.  2013a), magainin-AM2 (Ojo et al. 2015a) and 
tigerinin-1R (Ojo et al. 2015b) improve glucose tolerance in these mice. The present study has 
demonstrated that the potent but non-toxic analogues [P5K] and [D9k] analogues of hym-1B 
peptides also lowered blood glucose and enhanced insulin secretion in high-fat fed mice. 
Consistent with data from in vitro studies, [P5K]hym-1B displayed a greater effect on glucose 
tolerance than [D9k]hym-1B. Further studies are underway to study the effects of daily 
administration of [P5K]hym-1B over a period of 28 days on glucose tolerance and lipid profile in 
high-fat fed mice.  Future studies will also investigate effects of [P5K]hym-1B administration on 
islet cells morphology in obese mice.   
 
Materials and Methods 
Peptide synthesis and purification  
 
Hym-1B (IKLSPETKDNLKKVLKGAIKGAIAVAKMV.NH2) and its L-Lysine- and D-
Lysine-containing analogues were supplied in crude form by GL Biochem Ltd (Shanghai China) 
and were purified to near homogeneity (>98% purity) using reversed-phase HPLC as previously 
described (Mechkarska et al. 2013).  The identity of all peptides was confirmed by MALDI-TOF 
mass spectrometry using a Voyager DE PRO instrument (Applied Biosystems, Foster City, 
USA).  
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In vitro insulin release studies using BRIN-BD11 cells 
 
BRIN-BD11 rat clonal β-cells were cultured at 37 ˚C in an atmosphere of 5% CO2 and 95% 
air in RPMI-1640 tissue culture medium containing 10% (v/v) fetal calf serum, antibiotics (100 
U/mL penicillin, 0.1 mg/mL streptomycin) and 1.1 mM glucose as previously described 
(Srinivasan et al 2014). Cells were seeded into 24-multiwell plates and allowed to attach during 
overnight incubation at 37 ˚C. After incubation, the culture medium was removed and replaced 
with 1 ml Krebs-Ringer bicarbonate (KRB) buffer  containing 115 mM NaCl, 4.7 mM KCl, 1.28 
mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 20 mM HEPES, 25 mM NaHCO3 and 0.1% bovine 
serum albumin (BSA), supplemented with 1.1 mM glucose (pH 7.4) and incubated for 40 min at 
37 ˚C. After pre-incubation, incubations with purified synthetic peptides (10-12 – 3 x 10-6 µM; n = 
6) were carried out for 20 min at 37 ˚C using KRB buffer supplemented with 5.6 mM glucose. 
After incubation, aliquots of cell supernatant were removed for insulin radioimmunoassay (Flatt 
and Bailey 1981).  
   Additional incubations (n = 6)  with hym-1B (1 µM)  and  [P5K]hym-1B (1 µM)  were 
carried out in the presence of known modulators of insulin-release: (i) 16.7 mM glucose, (ii) 5.6 
mM glucose + diazoxide (300 µM), (iii) 5.6 mM glucose + verapamil (50 µM), and (iv)  16.7 mM 
glucose + 30 mM KCl.  The role of extracellular calcium in stimulated insulin release from BRIN-
BD11 cells was investigated by pre-incubating cells for 40 min with calcium-free KRB buffer pH 
7.4 containing 1.1mM glucose and 1mM EGTA followed by incubation for 20 min with hym-1B 
(1 µM)  and  [P5K]hym-1B (1 µM) in calcium-free KRB buffer containing 5.6 mM glucose .  
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Insulin-release studies using dispersed mouse islets 
 
Pancreatic islets were isolated from adult C57BL/6 mice as previously described (Lacy and 
Kostinosky 1967; Goto et al. 1985) by digestion with collagenase P obtained from Clostridium 
histolyticum (Sigma-Aldrich, Dorset, UK). After 48 h of culture, islets were pre-incubated with 
500 µL KRB containing 0.1% bovine serum albumin, and 1.4 mM glucose (pH 7.4) for 1 h at 37 
˚C. After pre-incubation, incubations with hym-1B and [P5K]hym-1B (0.1 nM - 1µM; n = 4) were 
carried out for 1 h at 37 ˚C using KRB buffer supplemented with 16.7 mM glucose. Control 
incubations were carried out in the presence of GLP-1 (1 µM). Aliquots of supernatant were 
removed for insulin radioimmunoassay. Islets were retrieved for later determination of islet insulin 
content following acid-ethanol extraction as previously described (Ojo et al. 2015).  
 
Cytotoxicity assay 
 
The effects of peptides on the rate of lactate dehydrogenase (LDH) release from BRIN-
BD11 cells were measured using the cell supernatants obtained from the acute insulin-release 
experiments. LDH concentrations were determined using a CytoTox 96 non-radioactive 
cytotoxicity assay kit (Promega, Southampton, UK) according to the manufacturer’s instructions 
as previously described (Ojo et al. 2013a). 
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Effects of peptides on membrane depolarization and intracellular calcium ([Ca2+] i) 
 
Effects of hym-1B (1 µM) and [P5K]hym-1B (1 µM) on membrane depolarization and 
intracellular Ca2+ concentrations were determined fluorimetrically with monolayers of BRIN-
BD11 cells using membrane potential and intracellular Ca2+assay kits Molecular Devices, 
Sunnyvale, CA, USA) according to the manufacturer’s recommended protocols as previously 
described (Abdel-Wahab et al 2008). Data were acquired using a FlexStation scanning fluorimeter 
with integrated fluid transfer workstation (Molecular Devices). The cells were incubated at 37 C 
for 10 min with peptides. Control incubations in the presence of 5.6 mM glucose only, 5.6 mM 
glucose + 30mM KCl, and 5.6 mM glucose + 10 mM alanine were also carried out.     
 
Effects of [P5K]hym-1B on cyclic AMP production 
 
Cells were seeded at a density of 2 x 105 per well in to 24 multi-well plate and allowed to 
attach overnight at 37 °C. Medium was discarded and cells were pre-incubated with KRB 
containing 1.1mM glucose (1 ml) for 40 min at 37 °C. Pre-incubation buffer was replaced by KRB 
buffer supplemented with 5.6mM glucose and 200µM of the phophodiesterase inhibitor, 3-
isobutyl-1-methylxanthine (IBMX) (1 ml), and the cells incubated for 20min. The supernatant was 
removed and stored for measurement of insulin concentration by radioimmunoassay. Thereafter, 
200µl of lysis buffer (1:5 dilution) was added to each well and cells were lysed by repeated freezing 
and thawing cycles. Cyclic AMP concentrations in the cell lysate were measured using a R & D 
Systems Parameter kit (Abingdon, UK) following the manufacturer’s recommended protocol.  
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Effects of down-regulation of the PKA and PKC pathways on insulin release 
 
BRIN-BD11 cells were seeded at a density of 1.5 x 105 cells per well in to 24 multi-well 
plate and allowed to attach during an 18 hour culture at 37 °C in an atmosphere of 5% CO2 and 
95% air.  Cells were cultured with forskolin (25µM; Sigma-Aldrich, UK) in experiments involving 
down-regulation of the protein kinase A (PKA) pathway, with phorbol 12-myristate 13-acetate  
(PMA; 10 nM; Sigma-Aldrich, UK)  for down-regulation of the protein kinase C (PKC) pathway, 
or with a combination of 25µM forskolin + 10nM PMA for down-regulation of both  pathways. 
Prior to the acute tests, cells were pre-incubated in 1ml KRB buffer (1 ml) supplemented with1.1 
mM glucose and 0.1% bovine serum albumin  (pH 7.4) for 40 min at 37 °C. Thereafter, the cells 
were incubated for 20 min in KRB buffer supplemented with 5.6mM glucose  (1ml) solution 
containing (i) [P5K]hym-1B (1µM), (ii) GLP-1 (10nM) and (iii) CCK8 (10 nM). Control 
incubations with forskolin (25µM), PMA (10nM) and forskolin (25µM) + PMA (10 nM) were also 
carried out.  
 
Effects of [P5K]-hymenochirin-1B on GLP- 1 release from GLUTag cells 
 
GLUTag cells (Drucker et al. 1992) were cultured and maintained at 37°C and atmosphere 
of 5% CO2 and 95% air in Dulbecco's Modified Eagle's medium (DMEM) media supplemented 
with 5.6mM glucose, 2 mM L-glutamine, and 10% foetal bovine serum as previously described 
(Ojo et al. 2013b). Cells were allowed to attach to 24 multi-well matrigel coated plates at a density 
of 1.5 x 105 cells per well during a 24 h incubation at 37 °C. Prior to the experiment, cells were 
pre-incubated in KRB buffer supplemented with 25mM HEPES, 1% BSA and 1 mM glucose (1 
19 
 
ml) for 45min at 37 °C. Test solutions were made in KRB buffer supplemented with 2mM glucose.  
After pre-incubation, the cells were incubated for 2 h at 37°C in KRB buffer containing 2 mM 
glucose (1ml) containing [P5K]hym-1B (10-12 M - 10-6 M ) or 10mM glutamine  as a positive 
control. The concentrations of GLP-1 in the supernatants were determined using a GLP-1 ELISA 
kit (Millipore, MA, USA) according to the manufacturer’s instructions.  
 
In vivo insulin release studies 
 
High-fat fed mice with clear manifestations of obesity, glucose intolerance and insulin 
resistance and age-matched lean mice (control) were used in the study.  Adult (8 week old), male, 
National Institutes of Health Swiss mice (Harlan Ltd, UK), were housed separately in an air-
conditioned room (22 ± 2 °C) with a 12-hour light: 12-hour dark cycle. Animals were maintained 
on a high-fat diet (45% kcal fat, 20% kcal protein, and 35% kcal carbohydrate) (Dietex 
International Ltd, Witham, UK) or on a standard rodent pellet diet (Trouw Nutrition, Northwich, 
UK) for 3 months before the experiment. All animal experiments were carried out in accordance 
with the UK Animals (Scientific Procedures) Act 1986 and EU Directive 2010/63EU for animal 
experiments and approved by Ulster University Animal Ethics Review Committee. All necessary 
steps were taken to ameliorate any potential animal suffering.  
Overnight fasted high-fat fed mice (n=8) were injected intraperitoneal with glucose alone 
(18mmol/kg body weight) or together with [P5K]hym-1B (75nmol/kg body weight) or [D9k]hym-
1B (75nmol/kg body weight). This peptide dose was chosen as a result of a preliminary study that 
determined acute effects of various concentrations of the peptides on glucose tolerance. Blood 
samples were collected as previously described (Srinivasan et al. 2014) before and after peptide 
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administration at the different time points shown in Fig. 8. Blood glucose concentrations were 
measured using an Ascencia Contour Blood Glucose Meter (Bayer, Newbury, UK). Plasma insulin 
concentrations were measured by radioimmunoassay.  
 
Statistical Analysis 
 
Data were compared using unpaired Student’s t test (non-parametric, with two-tailed P 
values and 95% confidence interval) and one way ANOVA with Bonferroni post-hoc test wherever 
applicable. Area under the curve (AUC) analysis was carried out using the trapezoidal rule with 
baseline correction. Values are presented as mean ± SEM.  Results are considered significant if p 
<0.05.  
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LEGEND TO FIGURES 
Figure 1: A comparison of the effects of (A) [P5K]-hymenochrin-1B, (B) [D9k]hymenochrin-1B, 
and (C) [E6K]-hymenochrin-1B with hymenochrin-1B on insulin release from BRIN-BD11 cells 
Values are mean ± SEM for n=8. *P<0.05, **P<0.01***P<0.001 compared to 5.6mM glucose 
alone. ΔP<0.05, ΔΔP<0.01, ΔΔΔP<0.001 compared to hymenochirin-1B  
 
Figure 2: A comparison of the effects of hymenochrin-1B and [P5K]hymenochrin-1B on (A) 
insulin  and (B) LDH release from isolated mouse islets. Values are mean ± SEM (n = 4). *P<0.05, 
**P<0.01, ***P<0.001 compared to 16.7 mM glucose. +P<0.05, ++P<0.01, +++P<0.001 compared 
to hymenochirin-1B. ΔP<0.05, ΔΔP<0.01, ΔΔΔP<0.001 compared to GLP-1 (10−6M). 
 
Figure 3: Effects of hymenochirin-1B and [P5K]hymenochrin-1B on membrane potential in 
BRIN-BD11 cells expressed as (A) relative fluorescence units, RFU and (B) area under the curve. 
Values are mean ± SEM (n = 6). ***P < 0.001 compared with 5.6 mM glucose alone. 
 
Figure 4: Effects of hymenochirin-1B and [P5K]hymenochrin-1B on intracellular calcium in 
BRIN-BD11 cells expressed as (A) relative fluorescence units, RFU and (B) area under the curve. 
Values are mean ± SEM (n = 6). ***P < 0.001 compared with 5.6 mM glucose alone. 
 
Figure 5: Effects of [P5K]hym-1B on cAMP production and insulin release in BRIN-BD 11 cells. 
Cells were incubated for 20 min at 37°C with control, [P5k]hym-1B or GLP-1 in KRB buffer 
supplemented with 5.6mM glucose + 200µM 3-isobutyl-1-methylxanthine (IBMX). Values are 
mean ± SEM for n=6. ***P<0.001 compared to 5.6mM glucose alone. ΔΔP<0.01, ΔΔΔP<0.001 
compared to 5.6mM glucose + IBMX. 
 
Figure 6: Effects of [P5K]hym-1B on insulin release from BRIN-BD11 cells following down 
regulation of the PKA and PKC pathways by overnight culture 25μM forskolin or 10nM PMA 
respectively. Values are mean ± SEM for n=8. ***P<0.001 compared to 5.6mM glucose, 
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ΔΔΔP<0.001 compared to respective incubation with normal culture, ϕϕP<0.01, ϕϕϕP<0.001 
compared to respective incubation with forskolin culture, ++P<0.01, +++P<0.001, compared to 
respective incubation with PMA culture. 
 
Figure 7: Effects of [P5K]-Hymenochirin-1B on GLP- 1 release from GLUTag cells. Glutamine 
(10mM) was used as positive control. Values are mean ± SEM for n=4. *P<0.05, ***P<0.001 
compared to 2mM glucose alone. 
 
Figure 8: Acute effects of administration of [P5K]hym-1B (75 nmol/kg body weight, A-D) and 
[D9k] hym-1B (75 nmol/kg body weight, E-H) on blood glucose and plasma insulin concentrations 
in high fat-fed  mice after intraperitoneal injection of glucose. Values are mean ± SEM (n =8). 
**P<0.01***P<0.001 compared to glucose alone.  
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LEGEND TO TABLES 
Table 1: Effects of hymenochirin-1B and its analogues on insulin release from BRIN-BD 11 cells. 
Basal release represents the rate of insulin release at 5.6 mM glucose alone and is set at 100%. 
Threshold concentration refers to the minimum concentration of the peptide producing a 
significant (P < 0.05) increase in the rate of insulin release. Values are mean ± SEM (n = 8). 
*P<0.05, ***P<0.001 compared to hymenochrin-1B at the same concentration.  
 
Table 2: Effects of hymenochirin-1B and analogues on insulin and LDH release from isolated 
mouse islets. Threshold concentration refers to the minimum concentration of the peptide 
producing a significant (P<0.05) increase in the rate of insulin release. Values are mean ± SEM (n 
= 4).  ***P<0.001 compared to 16.7mM glucose. ΔΔP<0.01 compared to GLP-1 (10-6M), ++P<0.01 
compared to hymenochirin-1B. 
 
Table 3: Effects of hymenochirin-1B and [P5K]hymenochirin-1B on insulin release from BRIN-
BD11 cells in the presence of established modulators of insulin secretion. Values are mean ± SEM 
(n = 6).  * P < 0.05, ***P<0.001 compared to appropriate glucose control. 
 
Table 4: Effects of hymenochirin-1B and [P5K]hymenochirin-1B on insulin release from BRIN-
BD11 cells in the absence of extracellular calcium. Values are mean ± SEM (n = 6).  ***P<0.001 
compared to appropriate glucose control.  
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Fig. 3 
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Fig. 4 
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Fig. 5 
0
250
500
750
1000
Glucose alone (5.6mM)
Glucose (5.6mM) + GLP-1 (10nM)
(A)
Glucose (5.6) + IBMX (200M)
Glucose (5.6mM) + IBMX (200M) + GLP-1 (10nM)
Glucose (5.6mM) + IBMX (200M) + [P5K]hymenochirin-1B (1M)
***
*
***
******


cA
M
P
 p
ro
du
ct
io
n
(p
m
ol
/m
l)
0
1
2
3
4
Glucose alone (5.6mM)
Glucose (5.6mM) + GLP-1 (10nM)
(B)
Glucose (5.6) + IBMX (200M)
Glucose (5.6mM) + IBMX (200M) + GLP-1 (10nM)
Glucose (5.6mM) + IBMX (200M) + [P5K]hymenochirin-1B (1M)
*** ***
******
 
In
su
lin
 r
el
ea
se
(n
g/
10
6  
ce
lls
/2
0m
in
)
 
 
 
33 
 
Fig. 6 
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Fig.7 
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Fig. 8 
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Table 1 
 
Peptide Threshold      
concentration 
(nM) 
Maximum non-toxic 
stimulatory 
concentration 
(µM) 
% of Basal insulin release at 
maximum non-toxic 
concentration 
 
Hymenochirin-1B 
[P5K]hymenochirin-1B 
[E6K]hymenochirin-1B 
[D9K]hymenochirin-1B 
[P5K,E6K]hymenochirin-1B 
[P5K,D9K]hymenochirin-1B 
[E6K, D9K]hymenochirin-1B 
[E6k]hymenochirin-1B 
[D9k]hymenochirin-1B 
[E6k,D9k]hymenochirin-1B 
1 
0.003 
0.003 
0.003 
0.003 
0.1 
0.01 
0.3 
0.01 
0.003 
1 
3 
1 
1 
0.3 
0.3 
0.1 
1 
3 
1 
304.4 ± 19.35 
568.5 ± 11.91*** 
459.7 ± 21.95*** 
404.8 ± 26.88* 
333.2 ± 25.70 
301.0 ± 12.34 
362.5 ± 14.24* 
312.0 ± 38.88 
486.4 ± 41.29** 
453.4 ± 29.76** 
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Table 2:  
 
Peptide                                                Threshold      
concentration 
(nM) 
Insulin release (% of 
total insulin content) 
at 1µM 
LDH release 
(% of release at 
16.7mM glucose) 
16.7mM glucose 
16.7mM glucose + GLP-1 (10-6 M) 
Hymenochirin-1B 
[P5K]hymenochirin-1B 
[D9k] hymenochirin-1B 
- 
- 
10 
0.1 
10 
7.64±0.32 
11.76±0.54*** 
13.36±0.07*** 
22.30±1.27***, ΔΔ, ++ 
17.76±1.46***, ΔΔ, ++ 
100.00±8.58 
100.55±5.47 
100.84±6.23 
100.78±7.12 
100.98±4.32 
 
 
 
 
 
 
. 
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Table 3:  
 
Groups 
Insulin Release 
(ng/106 cells/20min) 
5.6mM glucose 1.15±0.005 
5.6mM glucose+ Hym-1B (10-6 M) 2.65±0.27 *** 
5.6mM glucose+ [P5K]hym-1B (10-6 M) 5.98±0.81*** 
16.7mM glucose 2.66±0.11 
16.7mM glucose+ Hym-1B (10-6M) 4.25±0.21 *** 
16.7mM glucose+[P5K]hym-1B (10-6 M) 7.10±0.59 *** 
5.6mM glucose + 300µM Diazoxide 0.31±0.02 
5.6mM glucose + 300µM Diazoxide+ Hym-1B (10-6M) 0.80±0.04 *** 
5.6mM glucose + 300µM Diazoxide+ [P5K]hym-1B (10-6 M) 1.04±0.13*** 
5.6mM glucose + 50µM Verapamil 0.34±0.07 
5.6mM glucose + 50µM Verapamil+ Hym-1B (10-6 M) 1.40±0.09 * 
5.6mM glucose + 50µM Verapamil+ [P5K]hym-1B (10-6 M) 3.57±0.44 * 
16.7mM glucose + 30mM KCl 8.93±0.54  
16.7mM glucose + 30mM KCl+ Hym-1B (10-6 M) 12.11±0.86 * 
16.7mM glucose + 30mM KCl+ [P5K]hym-1B (10-6 M) 17.19±0.57*  
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Table 4:  
Groups Insulin Release 
(ng/106 cells/20min) 
5.6mM glucose 1.094±0.09 
5.6mM glucose+ Hym-1B (10-6 M) 2.07±0.13*** 
5.6mM glucose+ [P5K]hym-1B (10-6 M) 3.06±0.17*** 
5.6mM glucose (calcium free) 0.51±0.06 
5.6mM glucose (calcium free) + Hym-1B (10-6 M) 1.98±0.15*** 
5.6mM glucose (calcium free) + [P5K]hym-1B (10-6 M) 2.93±0.30*** 
 
 
 
